Want to join the conversation?
The generic drugmaker $MYL reported a fall in 3Q15 earnings due to higher operating expenses and tax benefit recorded in the previous year quarter on merger of its units into Mylan Labs. Net earnings fell to $428.6MM or $0.83 per share from $499.1MM or $1.26 per share last year. Revenue grew to $2.7Bil from $2.08Bil. Adjusted EPS grew 23% to $1.43.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.